After nearly three months of negotiations on July 20, the list of medicines for healthcare negotiations has been confirmed. On July 19, people club department website medicare drug directory access negotiations as a result, 36 drug was incorporated into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) "(hereinafter referred to as" drug catalogue ") b range. The ministry of human society synchronized the medical payment standards for these drugs. Among the 36 varieties, eight a-share listed companies have been shortlisted for new drugs, the reporter found. The head of a listed company told reporters that the inclusion of the health care catalogue will benefit more patients, and the company's sales volume is expected to expand further to improve its performance.
According to the understanding, the total of 44 drugs involved in the negotiation, 36 of the successful negotiations, were integrated into the category b category, with a success rate of 81.8%. Negotiation of payment standard compared to the average retail price of 2016, the average decline of 44%, the highest drop of 70%, significantly reduce the burden of ginseng protect personnel expenses for medicine, but also effectively control the medical insurance fund spending.
The 36 drugs successfully negotiated included 31 western medicines and five herbal medicines. 31 in western medicine, 15 is a cancer treatment drug, involving the common cancer such as lung cancer, gastric cancer, breast cancer and multiple myeloma, including the previous ginseng protect personnel to reflect more by bead sheet resistance, rituxan, boron for Mr M, drug lenalidomide, etc; Five are cardiovascular drugs; Other drugs are nephropathy, ophthalmology, psychosis, anti-infection, diabetes and rare diseases. Three of the five Chinese medicines are tumor drugs and two are cardiovascular and cerebrovascular drugs.
Notable is that the negotiations on the innovation medicine attaches great importance to and rare diseases, major drug discovery projects listed in the "twelfth five-year" since the country's west of the amine, compaq heap, path for, all negotiations success, such as the restructuring of the treatment of hemophilia people Ⅶ a clotting factors and treatment of multiple sclerosis of human recombinant interferon beta 1 b are successfully incorporated into drug directory.
Yesterday, people club department deputy director of the social security center, Mr. Xu said in an interview, through negotiations will have strong social targeted medicine major diseases such as cancer treatment in medicine directory, greatly improve the security level of the basic medical insurance, but also take into account the fund burden ability, and is helpful to guide the reasonable medical behavior, promote the development of medicine industry innovation, health care, business has been basically achieved, ginseng protect people "win-win-win" goals. "Next, we will guide the local government to earnestly implement the results of the negotiations and ensure that this important policy of benefiting the people can be implemented at an early date so that the people of the people can truly benefit."
Reporter noted that in 36 negotiations successful varieties, including tasly, hundred million sails medicine, letter litai 8 listed company such as blockbuster variety, is expected to bring the Gospel to people in the major disease treatment, such as hengrui pharmaceutical blockbuster drugs mesylate path for tablets (cancer of the stomach medication), hundred million sails medicine exclusive varieties compound Huang Dai drug (leukemia), yasuhiro miyata class of pharmaceutical drug compaq heap eye ophthalmic injection (drug fundus macular degeneration), o letter litai a class of new drugs to the sand jotham ester (blood pressure medication), and both anticancer drugs of traditional Chinese medicine monomer CanYi capsule, etc.
It is reported that the injection recombinant human urokinase was a new class of new drugs listed in 2011, which is a major innovation of major new drugs in China. The drug is mainly used for the treatment of acute myocardial infarction caused by thrombosis, which has advantages in efficacy and price compared with other foreign species, and it is expected to be over 10 billion varieties in the future.
Also, the exclusive variety of the compound of the compound huangdai film company of yifan medicine is mainly used for the treatment of leukaemia. , head of the company after accepting a reporter to interview, said: "before the product has entered the local medical insurance directory, the directory into the negotiations this week hope to further expand product sales. However, sales growth will also need a time process, in the short term will not take effect immediately." It is worth mentioning that in this year's new edition of the health care catalogue, there are 11 major varieties of yifan medicine, which is a good harvest. The company said the inclusion of products in the health care catalog would benefit more patients and would also help improve the company's performance.
Social security institute, vice President of China, national sun yat-sen university governance research institute, vice President of professor shu-guang shen said in an interview with the Shanghai newspaper reporters, health talks drugs on the one hand reflects the state of innovation of the medicine industry of affirmation and support, to further encourage domestic drug firms innovation research and development, on the other hand, also from the point of view of medical insurance fund safeguard the shift disease medication, helps to reduce the economic burden of patients, has the vital significance. |
